Extracorporeal Shockwave Therapy for Diabetic Foot Ulcers
Key facts
- Who runs it
- Hull University Teaching Hospitals NHS Trust
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 77 people enrolled
- Started
- 13 Apr 2022
- Expected to end
- 1 May 2032
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Extracorporeal Shockwave Therapy
- Record updated
- 18 June 2026
Who can take part
- Age
- 18 years to 120 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- At least one unhealed diabetic foot ulcer below the level of the medial malleoli that has been present for more than 4 weeks
- Absolute toe pressure greater than or equal to 50mmHg or an Ankle Pressure Brachial Index (ABPI) equal to or greater than 0.7(24, 25)
- Capacity to consent to participate in the trial and given written informed consent
- Willing to be randomised to either sham, low-dose or high-dose ESWT
- Willing to consent to photography of the index DFU
- Willing to comply with the follow up schedule
Who cannot take part
- Currently on or planned treatment for osteomyelitis
- Currently taking any therapeutic anticoagulation medications. This includes novel oral anticoagulants, therapeutic doses of heparin and vitamin-K antagonists. This is a contraindication to ESWT
- Interdigital index ulcer. This is because the ESWT delivery paddle does not fit between digits
- Diagnosis of malignancy in the treatment area or haematological, disseminated or lymphatic malignancy. This is a contraindication to ESWT
- All who are pregnant, trying to conceive or breastfeeding. This is a contraindication to ESWT
- Active participants in other trials that may conflict with the study outcomes, for example any other wound care trials
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Summary of the problem:
Read full original descriptionShow less
Diabetes has been described as the fastest growing health crisis of our time. It currently affects more than 4.5million people in the UK. The direct cost to the NHS is already over £1 billion per year. One of the commonest complications of diabetes are foot ulcers. Despite current best treatment, these ulcers can be very difficult to heal, often taking months to heal and some never do. Even after healing ulcers return in up to 60% of people. In England someone undergoes an amputation of part of their foot every 2 hours and every 4 hours someone loses their leg due to diabetic foot ulcers. People are rarely able to be as active as before. This seriously affects their work, finances and quality of life.
Research into improved treatments are a national priority. These treatments need to be safe, effective, tolerable for patients and value for money. Preliminary research has identified shockwave therapy as a promising new treatment in which high-power soundwaves (similar to ultrasound) are delivered to the ulcer. This may make ulcers heal faster. However, the effectiveness of shockwave therapy and the optimum dose is unknown.
The aim of the study:
1. To carry out a preliminary (pilot) trial comparing sham (not active) shockwaves, low number of shockwaves and high number of shockwaves on diabetic foot ulcer healing 2. To understand beliefs, concerns, ideas and experience of shockwave therapy amongst patients and clinicians 3. To investigate the cost effectiveness (value for money) of shockwave therapy
Methods
1. Pilot Trial: Ninety patients with DFU will be randomly assigned to one of three treatment groups:
1. High dose shockwave treatment 2. Low dose shockwave treatment 3. "Sham" shockwave treatment
Each treatment will be delivered in 3x30minute sessions in a 7-day period. Face-to-face follow up appointments will take place 1, 2, 3 and 6 months after treatment to measure ulcer healing and changes in quality-of-life.
Interviews Interviews to explore patient opinion of shockwave therapy, experience in taking part in the trial, reasons patients do not want to take part and clinician attitudes to shockwave therapy
The 3 groups in the trial
- Sham shockwave therapySham treatment, for comparison
Sham shockwave therapy in standard ulcer care.
Treatment: Extracorporeal Shockwave Therapy
- Low dose shockwave therapyExisting treatment, for comparison
100 shocks per cm2 plus standard ulcer care
Treatment: Extracorporeal Shockwave Therapy
- High dose shockwave therapyExisting treatment, for comparison
500 shocks per cm2 plus standard ulcer care
Treatment: Extracorporeal Shockwave Therapy
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Extracorporeal Shockwave Therapy for Diabetic Foot Ulcers: A Pilot 3-Arm Randomised Control Trial and Qualitative Study (SOLEFUL).
- Publications
- Record updated
- 18 June 2026